Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.67 |
| ▸ | HSP90AA1 | P07900 | 6/20 | 0.53 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.53 |
| ▸ | HSP90B1 | P14625 | 2/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.49 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.46 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.46 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | GRAMD1A | Q96CP6 | 1/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.42 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31073472 | 0.90 | MAPT (0.55) | MAPTHSP90AA1HSP90AB1HSP90B1ESR2 | |
| SCHEMBL20078108 | 0.88 | DDB1 (0.53) | MAPTHSP90AA1HSP90AB1HSP90B1ESR2 | |
| SCHEMBL30378007 | 0.87 | MAPT (0.67) | MAPTHSP90AA1HSP90AB1HSP90B1ESR2 | |
| SCHEMBL25574538 | 0.87 | MAPT (0.67) | MAPTHSP90AA1HSP90AB1HSP90B1ESR2 | |
| SCHEMBL29757600 | 0.86 | MAPT (0.65) | MAPTHSP90AA1HSP90AB1ESR2NR1H2 | |
| SCHEMBL19475563 | 0.86 | MAPT (0.65) | MAPTHSP90AA1HSP90AB1ESR2NR1H2 | |
| SCHEMBL3530060 | 0.86 | MAPT (0.65) | MAPTHSP90AB1ESR2NR1H2DDB1 | |
| SCHEMBL17183931 | 0.86 | MAPT (0.65) | MAPTHSP90AA1HSP90AB1ESR2NR1H2 | |
| SCHEMBL3878893 | 0.85 | MAPT (0.64) | MAPTHSP90AA1HSP90B1ESR2NR1H2 | |
| SCHEMBL29448378 | 0.85 | MAPT (0.64) | MAPTHSP90AA1HSP90B1ESR2NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180036317-A1 | METHOD OF TREATING CONDITIONS WITH KINASE INHIBITORS | ALLERGAN INC (US) | 2018-02-08 | — | — | US | disclosed |
| US-9820989-B2 | Method of treating conditions with kinase inhibitors | ALLERGAN, INC. (US) | 2017-11-21 | — | — | US | disclosed |
| US-20170143728-A1 | METHOD OF TREATING CONDITIONS WITH KINASE INHIBITORS | ALLERGAN, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20170057966-A1 | FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS | AbbVie Deutschland GmbH & Co. KG (DE) | 2017-03-02 | — | — | US | disclosed |
| US-9388176-B2 | Method of treating conditiions with kinase inhibitors | ALLERGAN, INC. (US) | 2016-07-12 | — | — | US | disclosed |
| US-8889870-B2 | Kinase inhibitors | ALLERGAN, INC. (US) | 2014-11-18 | — | — | US | disclosed |
| US-20130237538-A1 | KINASE INHIBITORS | ALLERGAN, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-20130237537-A1 | METHOD OF TREATING CONDITIIONS WITH KINASE INHIBITORS | ALLERGAN, INC. (US) | 2013-09-12 | — | — | US | disclosed |
| US-7388019-B2 | 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK & CO., INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-20060074087-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | MERCK SHARP & DOHME LLC | 2006-04-06 | — | — | US | disclosed |
| US-6653302-B2 | Benign prostatic hyperplasia | PFIZER INC. | 2003-11-25 | — | — | US | disclosed |
| US-20030130259-A1 | Quinoline and quinazoline compounds useful in therapy | FOX DAVID NATHAN ABRAHAM (GB) | 2003-07-10 | — | — | US | disclosed |
| EP-0968208-B1 | QUINOLINE AND QUINAZOLINE COMPOUNDS USEFUL IN THERAPY, PARTICULARLY IN THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | PFIZER LTD (GB) | 2003-06-04 | — | — | EP | disclosed |
| US-6521629-B2 | 2-amine substituted quinoline or quinozoline derivatives useful for treating benign prostatic hyperplasia | PFIZER INC. | 2003-02-18 | — | — | US | disclosed |
| US-20020040028-A1 | Quinoline and quinazoline compounds useful in therapy | FOX DAVID NATHAN ABRAHAM (GB) | 2002-04-04 | — | — | US | disclosed |
| US-6365599-B1 | FOR THERAPY OF BENIGN PROSTATIC HYPERPLASIA | PFIZER, INC. | 2002-04-02 | — | — | US | disclosed |
| US-6169093-B1 | FOR TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | PFIZER INC. | 2001-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074087-A1 | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes | DPP4, DPP3, DPP7 | MAPT 3014/4885HSP90AA1 3454/4885HSP90AB1 3373/4885 |
| US-20180036317-A1 | METHOD OF TREATING CONDITIONS WITH KINASE INHIBITORS | MAP3K1, MAPK1, MAP3K2 | MAPT 2008/4885HSP90AA1 2744/4885HSP90AB1 1951/4885 |
| US-20170057966-A1 | FUSED HETEROCYCLIC COMPOUNDS AS S1P MODULATORS | S1PR1, S1PR2, S1PR3 | MAPT 3696/4885HSP90AA1 2959/4885HSP90AB1 2597/4885 |
| US-20030130259-A1 | Quinoline and quinazoline compounds useful in therapy | NQO2, RFT1, LPXN | MAPT 3009/4885HSP90AA1 3672/4885HSP90AB1 3184/4885 |
| US-20020040028-A1 | Quinoline and quinazoline compounds useful in therapy | BPHL, LPXN, NQO2 | MAPT 2899/4885HSP90AA1 3762/4885HSP90AB1 3254/4885 |
| US-20170143728-A1 | METHOD OF TREATING CONDITIONS WITH KINASE INHIBITORS | MAP3K1, MAPK1, MAP3K2 | MAPT 2008/4885HSP90AA1 2744/4885HSP90AB1 1951/4885 |
| US-20130237537-A1 | METHOD OF TREATING CONDITIIONS WITH KINASE INHIBITORS | CDK5, MAP3K1, ALDH1A2 | MAPT 2168/4885HSP90AA1 1912/4885HSP90AB1 1156/4885 |
| US-20130237538-A1 | KINASE INHIBITORS | MAP3K1, MAP3K6, MAP3K2 | MAPT 3468/4885HSP90AA1 1111/4885HSP90AB1 800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.